Damaging effects of hyperglycemia on cardiovascular function: Spotlight on glucose metabolic pathways

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 310, Issue 2, 2016, Pages H153-H173

  Mapanga, Rudo F ^a   Essop, M Faadiel ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Advanced glycation end products; Cardiovascular diseases; Hexosamine biosynthetic pathway; Hyperglycemia; Polyol pathway

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEXOSAMINE; POLYOL; PROTEIN KINASE C;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIUM CELL; GLUCOSE METABOLISM; HEART INJURY; HUMAN; HYPERGLYCEMIA; INCIDENCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; GLUCOSE; HUMANS; HYPERGLYCEMIA; METABOLIC NETWORKS AND PATHWAYS;

EID: 84954508083     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00206.2015     Document Type: Review

References (350)

1. A Ahmed K, Muniandy S, S Ismail I. Role of N-(carboxymethyl)lysine in the development of ischemic heart disease in type 2 diabetes mellitus. J Clin Biochem Nutr 41: 97-105, 2007
2. Abordo E, Minhas H, Thornalley P. Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem Pharmacol 58: 641-648, 1999
3. Ahmed MU, Dunn JA, Walla MD, Thorpe SR, Baynes JW. Oxidative degradation of glucose adducts to protein. J Biol Chem 263: 8816-8821, 1988
4. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 67: 3-21, 2005
5. Aiello L. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 47: S263-S269, 2002
6. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM. NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 47: 15-22, 2009
7. Al Rifai M, Schneider AL, Alonso A, Maruthur N, Parrinello CM, Astor BC, Hoogeveen RC, Soliman EZ, Chen LY, Ballantyne CM, Halushka MK, Selvin E. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications 29: 180-185, 2015
8. Ananthakrishnan R, Kaneko M, Hwang YC, Quadri N, Gomez T, Li Q, Caspersen C, Ramasamy R. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 296: H333-H341, 2009
9. Aneja A, Tang W, Bansilal S, Garcia M, Farkouh M. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121: 748-757, 2008
10. Annapurna A, Challa SR, Prakash GJ, Viswanath RK. Therapeutic potential of sulindac against ischemia-reperfusion-induced myocardial infarction in diabetic and nondiabetic rats. Exp Clin Cardiol 13: 66-70, 2008
11. Argirova MD, Ortwerth BJ. Activation of protein-bound copper ions during early glycation: study on two proteins. Arch Biochem Biophys 420: 176-184, 2003
12. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar M, Lopez S, Williams C, Torres R, Wagle D, Ulrich P, Cerami A, Brines M, Regan T. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 97: 2809-2813, 2000
13. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37: 87-92, 2000
14. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120, 2003
15. Babior B. NADPH oxidase: an update. Blood 93: 1464-1476, 1999
16. Balteau M, Tajeddine N, de Meester C, Ginion A, Des Rosiers C, Brady NR, Sommereyns C, Horman S, Vanoverschelde JL, Gailly P, Hue L, Bertrand L, Beauloye C. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res 92: 237-246, 2011
17. Baynes J. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991
18. Baynes JW, Thorpe SR. The role of oxidative stress in diabetic complications. Curr Opin Endocrinol 3: 277-284, 1996
19. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002
20. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase C_ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90: 107-111, 2002
21. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 29: 6S95-6S103, 2003
22. Beneke S, Bürkle A. Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res 35: 7456-7465, 2007
23. Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26: 2791-2795, 2003
24. Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M, Dincer D, Besch HR. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium release channels. Diabetes 52: 1825-1836, 2003
25. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, Besch HR. Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2_-ATPase. Diabetes 53: 463-473, 2004
26. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50: 2792-2808, 2001
27. Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced ßII PKC activation. Am J Physiol Heart Circ Physiol 280: H621-H627, 2001
28. Bohlen HG. Protein kinase ßII in Zucker obese rats compromises oxygen and flow-mediated regulation of nitric oxide formation. Am J Physiol Heart Circ Physiol 286: H492-H497, 2004
29. Bolton W, Cattran D, Williams M, Adler S, Appel G, Cartwright K, Foiles P, Freedman B, Raskin P, Ratner R, Spinowitz B, Whittier F, Wuerth J; ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24: 32-40, 2004
30. Bonnefont-Rousselot D, Bastard J, Jaudon M, Delattre J. Consequences of diabetic status on the oxidant/antioxidant balance. Diabetes Metab 26: 163-176, 2000
31. Boschetto P, Campo I, Stendardo M, Casimirri E, Tinelli C, Gorrini M, Ceconi C, Fucili A, Potena A, Papi A, Ballerin L, Fabbri L, Luisetti M. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest 43: 562-569, 2013
32. Bowes A, Khan M, Shi Y, Robertson L, Werstuck G. Valproate attenuates accelerated atherosclerosis in hyperglycemic apoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis. Am J Pathol 174: 330-342, 2009
33. Bozdağ-Dündar O, Verspohl E, Daş-Evcimen N, Kaup R, Bauer K, Sarikaya M, Evranos B, Ertan R. Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones. Bioorg Med Chem 16: 6747-6751, 2008
34. Branchetti E, Bavaria JE, Grau JB, Shaw RE, Poggio P, Lai EK, Desai ND, Gorman JH, Gorman RC, Ferrari G. Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve and associated aortopathies. Arterioscler Thromb Vasc Biol 34: 2349-2357, 2014
35. Brett J, Schmidt a M, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712, 1993
36. Brouwers O, Niessen PM, Haenen G, Miyata T, Brownlee M, Stehouwer CD, De Mey JG, Schalkwijk CG. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 53: 989-1000, 2010
37. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001
39. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625, 2005
40. Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM, Ramasamy R. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57: 1941-1951, 2008
41. Buettner G. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300: 535-543, 1993
42. Bürkle A. Poly(ADP-ribose). The most elaborate metabolite of NAD_. FEBS J 272: 4576-4589, 2005
43. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Asso-ciation, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115: 114-126, 2007
44. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 290: E1-E8, 2006
45. Cai L, Wang J, Li Y, Sun X, Wang L. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 54: 1829-1837, 2005
46. Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, Cooper ME, Jandeleit-Dahm KA. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 51: 1731-1740, 2008
47. Cameron NE, Cotter MA. Contraction and relaxation of aortas from galactosaemic rats and the effects of aldose reductase inhibition. Eur J Pharmacol 243: 47-53, 1993
48. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 35: 1011-1019, 1992
49. Cao W, Chen J, Chen Y, Chen X, Liu P. Advanced glycation end products promote heart failure trough inducing the immune maturation of dendritic cells. Appl Biochem Biotechnol 172: 4062-4077, 2014
50. Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER. Glucose-induced oxidative stress in mesangial cells. Kidney Int 61: 599-608, 2002
51. Cellek S, Qu W, Schmidt A, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 47: 331-339, 2004
52. Ceriello A, Morocutti A, Mercuri F, Quagliaro L, Moro M, Damante G, Viberti G. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 49: 2170-2177, 2000
53. Ceriello A, Quagliaro L, D’Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51: 1076-1082, 2002
54. Chang KC, Liang JT, Tsai PS, Wu MS, Hsu KL. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol 157: 1419-1426, 2009
55. Chang KC, Paek KS, Kim HJ, Lee YS, Yabe-Nishimura C, Seo HG. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 61: 1184-1191, 2002
56. Chatham JC, Forder JR. A C-NMR study of glucose oxidation in the intact functioning rat heart following diabetes-induced cardiomyopathy. J Mol Cell Cardiol 25: 1203-1213, 1993
57. Chatham JC, Marchase RB. The role of protein O-linked beta-Nacetylglucosamine in mediating cardiac stress responses. Biochim Biophys Acta 1800: 57-66, 2010
58. Chatham JC, Nöt LG, Fülöp N, Marchase RB. Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. Shock 29: 431-440, 2008
59. Chen F, Kumar S, Yu Y, Aggarwal S, Gross C, Wang Y, Chakraborty T, Verin AD, Catravas JD, Lucas R, Black SM, Fulton DJ. PKC-dependent phosphorylation of eNOS at T495 regulates eNOS coupling and endothelial barrier function in response to G-toxins. PLoS One 9: e99823, 2014
60. Churchill EN, Ferreira JC, Brum PC, Szweda LI, Mochly-Rosen D. Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc Res 85: 385-394, 2010
61. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, Dillman WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear OGlcNAcylation. J Biol Chem 278: 44230-44237, 2003
62. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, DeMicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 60: 2379-2385, 2011
63. Colussi C, Albertini M, Coppola S, Rovidati S, Galli F, Ghibelli L. H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis. FASEB J 14: 2266-2276, 2000
64. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, Thai K, Krum H, Gilbert RE. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2: 129-137, 2009
65. Coomer M, Essop MF. Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes. Mol Genet Metab Reports 1: 158-169, 2014
66. Cotter M, Cameron N, Robertson S. Polyol pathway-mediated changes in cardiac muscle contractile properties: studies in streptozotocin-diabetic and galactose-fed rats. Exp Physiol 77: 829-838, 1992
67. Crabbe M, Goode D. Aldose reductase: a window to the treatment of diabetic complications? Prog Retin Eye Res 17: 313-383, 1998
68. Cromlish J, Flynn T. Purification and characterization of an enzymically active cleavage product of pig kidney aldehyde reductase. Biochem J 209: 597-607, 1983
69. Cromlish J, Yoshimoto C, Flynn T. Purification and characterization of four NADPH-dependent aldehyde reductases from pig brain. J Neurochem 44: 1477-1484, 1985
70. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Suppression of rage as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26: 2716-2723, 2006
71. Daoud S, Schinzel R, Neumann A, Loske C, Fraccarollo D, Diez C, Simm A. Advanced glycation endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Mol Med 7: 543-551, 2001
72. Das Evcimen N, King G. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498-510, 2007
73. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol 4: 301-305, 2004
74. den Dekker MA, Zwiers M, van den Heuvel ER, de Vos LC, Smit AJ, Zeebregts CJ, Oudkerk M, Vliegenthart R, Lefrandt JD, Mulder DJ. Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis. PLoS One 8: e83084, 2013
75. Deora AA, Win T, Vanhaesebroeck B, Lander HM. A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3=-kinase to Ras by redox stress. J Biol Chem 273: 29923-29928, 1998
76. Desco M, Asensi M, Márquez R, Martínez-Valls J, Vento M, Pallardó F, Sastre J, Viña J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 51: 1118-1124, 2002
77. DeSouza C, Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov 8: 361-367, 2009
78. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986, 1993
79. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42: 328-335, 2003
80. Diefenbach J, Bürkle A. Introduction to poly(ADP-ribose) metabolism. Cell Mol Life Sci 62: 721-730, 2005
81. Diguet N, Mallat Y, Ladouce R, Clodic G, Prola A, Tritsch E, Blanc J, Larcher JC, Delcayre C, Samuel JL, Friguet B, Bolbach G, Li Z, Mericskay M. Muscle creatine kinase deficiency triggers both actin depolymerization and desmin disorganization by advanced glycation end products in dilated cardiomyopathy. J Biol Chem 286: 35007-35019, 2011
82. D’Souza DR, Salib MM, Bennett J, Mochin-Peters M, Asrani K, Goldblum SE, Renoud KJ, Shapiro P, Passaniti A. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. J Biol Chem 284: 17947-17955, 2009
83. Du X, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-1348, 2001
84. Du X, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97: 12222-12226, 2000
85. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049-1057, 2003
86. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 77: S3-S12, 2000
87. Durpes MC, Morin C, Paquin-Veillet J, Beland R, Pare M, Guimond MO, Rekhter M, King GL, Geraldes P. PKC-_ activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res 106: 303-313, 2015
88. Dworakowski R, Alom-Ruiz SP, Shah AM. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep 60: 21-28, 2008
89. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 25: 65-70, 2005
90. Epidemiology of Diabetes Interventions, and Complications (EDIC) study. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
91. Federici M, Menghini R, Mauriello A, Hribal M, Ferrelli F, Lauro D, Sbraccia P, Spagnoli L, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106: 466-472, 2002
92. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy Cardiovasc Drugs Ther 8: 65-73, 1994
93. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 69: 788-797, 2006
94. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51, 2001
95. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 7: 313-324, 2011
96. Forbes J, Cooper M, Thallas V, Burns W, Thomas M, Brammar G, Lee F, Grant S, Burrell L, Jerums G, Osicka T. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51: 3274-3282, 2002
97. Fricovsky ES, Suarez J, Ihm SH, Scott BT, Suarez-Ramirez JA, Banerjee I, Torres-Gonzalez M, Wang H, Ellrott I, Maya-Ramos L, Villarreal F, Dillmann WH. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 303: R689-R699, 2012
98. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 12: 5, 2013
99. Gabriely I, Yang X, Cases J, Ma X, Rossetti L, Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 160: 115-122, 2002
100. +exchanger- 1 inhibitors decrease myocardial superoxide production via direct mitochondrial action. J Appl Physiol 105: 1706-1713, 2008
101. Garson K, Mapanga RF, Milne R, Essop MF. The effects of benfotiamine in attenuating hyperglycemia-induced cardiac pathology. J African Assoc Physiol Sci 2: 5-13, 2010
102. Gawlowski T, Stratmann B, Stirban AO, Negrean M, Tschoepe D. AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation. Thromb Res 121: 117-126, 2007
103. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106: 1319-1331, 2010
104. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010
105. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol 28: 1137-1143, 2008
106. Goldberg H, Whiteside C, Fantus I. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J Biol Chem 277: 33833-33841, 2002
107. Goldberg H, Whiteside C, Hart G, Fantus I. Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. Endocrinology 147: 222-231, 2006
108. González R, Barnett P, Cheng H, Chylack LJ. Altered phosphate metabolism in the intact rabbit lens under high glucose conditions and its prevention by an aldose reductase inhibitor. Exp Eye Res 39: 553-562, 1984
109. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994
110. Guo M, Wu M, Korompai F, Yuan S. Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics 12: 139-146, 2003
111. Guzik T, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon K. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002
112. Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans 35: 1147-1150, 2007
113. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 228: 539-543, 1996
114. Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients. Life Sci 57: 23-29, 1995
115. Hammes H, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558, 1991
116. Hanover J, Forsythe M, Hennessey P, Brodigan T, Love D, Ashwell G, Krause M. A Caenorhabditis elegans model of insulin resistance: altered macronutrient storage and dauer formation in an OGT-1 knockout. Proc Natl Acad Sci USA 102: 11266-11271, 2005
117. Hara A, Harada T, Nakagawa M, Matsuura K, Nakayama T, Sawada H. Isolation from pig lens of two proteins with dihydrodiol dehydrogenase and aldehyde reductase activities. Biochem J 264: 403-407, 1989
118. Harja E, Chang JS, Lu Y, Leitges M, Zou YS, Schmidt AM, Yan SF. Mice deficient in PKC and apolipoprotein E display decreased atherosclerosis. FASEB J 23: 1081-1091, 2009
119. Hecker PA, Mapanga RF, Kimar CP, Ribeiro RF, Brown BH, O’Connell KA, Cox JW, Shekar KC, Asemu G, Essop MF, Stanley WC. Effects of glucose-6-phosphate dehydrogenase deficiency on the metabolic and cardiac responses to obesogenic or high-fructose diets. Am J Physiol Endocrinol Metab 303: E959-E972, 2012
120. Heier M, Margeirsdottir HD, Torjesen PA, Seljeflot I, Stensaeth KH, Gaarder M, Brunborg C, Hanssen KF, Dahl-Jørgensen K. The advanced glycation end product methylglyoxal-derived hydroimidazolone- 1 and early signs of atherosclerosis in childhood diabetes. Diabetes Vasc Dis Res 12: 139-145, 2015
121. Herrmann KL, McCulloch AD, Omens JH. Glycated collagen crosslinking alters cardiac mechanics in volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 284: H1277-H1284, 2003
122. Hers H. The mechanism of the transformation of glucose in fructose in the seminal vesicle. Biochim Biophys Acta 22: 202-203, 1956
123. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O’Brien R, Cooper ME, Chin-Dusting JP, Sviridov D. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50: 1770-1779, 2007
124. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 28: 2275-2281, 2008
125. Hong J, Ku SH, Lee MS, Jeong JH, Mok H, Choi D, Kim SH. Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction. Biomaterials 35: 7562-7573, 2014
126. Hoshi A, Takahashi M, Fujii J, Myint T, Kaneto H, Suzuki K, Yamasaki Y, Kamada T, Taniguchi N. Glycation and inactivation of sorbitol dehydrogenase in normal and diabetic rats. Biochem J 318, Pt 1: 119-123, 1996
127. Hu Y, Belke D, Suarez J, Swanson E, Clark R, Hoshjima M, Dillman WH. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 96: 1006-1013, 2005
128. Huang JS, Guh JY, Hung WC, Yang ML, Lai YH, Chen HC, Chuang LY. Role of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) cascade in advanced glycation endproduct- induced cellular mitogenesis in NRK-49F cells. Biochem J 342: 231-238, 1999
129. Hunt J, Dean R, Wolff S. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 256: 205-212, 1988
130. Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis 231: 315-322, 2013
131. Hwang YC, Bakr S, Ellery CA, Oates PJ, Ramasamy R. Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J 18: 2331-2333, 2003
132. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, Yan S, Ii S, Itakura M, Rui L, Skopicki H, Homma S, Schmidt AM, Oates PJ, Szabolcs M, Ramasamy R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 18: 1192-1199, 2004
133. Hwang YC, Sato S, Tsai JY, Bakr S, Yan SD, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J 16: 243-245, 2002
134. Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH. Peroxisome proliferator-activated receptor-_ activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol 105: 399-407, 2010
135. Ikeda A, Matsushita S, Sakakibara Y. Inhibition of protein kinase Cß ameliorates impaired angiogenesis in type I diabetic mice complicating myocardial infarction. Circ J 76: 943-949, 2012
136. Imbriolo J, Mapanga RF, Essop MF. The hexosamine biosynthetic pathway induces gene promoter activity of acetyl-CoA carboxylase beta. Biochem Biophys Res Commun 452: 734-739, 2014
137. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89: 11059-11063, 1992
138. Inskeep P, Ronfeld R, Peterson M, Gerber N. Pharmacokinetics of the aldose reductase inhibitor, zopolrestat, in humans. J Clin Pharmacol 34: 760-766, 1994
139. Inskeep PB, Reed AE, Ronfeld RA. Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. Pharm Res 8: 1511-1515, 1991
140. Ishii H, Jirousek M, Koya D, Takagi C, Xia P, Clermont A, Bursell S, Kern T, Ballas L, Heath W, Stramm L, Feener E, King G. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731, 1996
141. Iwata N, Inazu N, Satoh T. The purification and properties of aldose reductase from rat ovary. Arch Biochem Biophys 282: 70-77, 1990
142. Joseph D, Kimar C, Symington B, Milne R, Essop MF. The detrimental effects of acute hyperglycemia on myocardial glucose uptake. Life Sci 105: 31-42, 2014
143. Jyothirmayi G, Soni B, Masurekar M, Lyons M, Regan T. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Ther 3: 319-326, 1998
144. Kaiserova K, Srivastava S, Hoetker JD, Awe SO, Tang X, Cai J, Bhatnagar A. Redox activation of aldose reductase in the ischemic heart. J Biol Chem 281: 15110-15120, 2006
145. Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Oda N, Hidaka T, Kihara Y, Chayama K, Goto C, Aibara Y, Noma K, Takeuchi M, Matsui T, Yamagishi S, Higashi Y. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 38: 119-125, 2015
146. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34: 29-34, 1974
147. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley P. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 31: 1423-1425, 2003
148. Kasuya Y, Ito M, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T, Naruse K, Nakashima E, Kato K, Koh N, Hotta N. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs. Diabetologia 42: 1404-1409, 1999
149. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, Aizawa T, Fu LT. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 19: 415-420, 2008
150. Khan ZA, Chakrabarti S. Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007: 31867, 2007
151. Khullar M, Al-Shudiefat A, Ludke A, Binepal G, Singal P. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol 88: 233-240, 2010
152. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50: 1409-1417, 2007
153. King G, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25: 255-270, 1996
154. King G, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122: 333-338, 2004
155. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85: 87-91, 2001
156. Knecht E, Roche E. The reduction-oxidation status may influence the degradation of glyceraldehyde-3-phosphate dehydrogenase. FEBS Lett 206: 339-342, 1986
157. Kong L, Shen X, Lin L, Leitges M, Rosario R, Zou YS, Yan SF. PKCß promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. Arterioscler Thromb Vasc Biol 33: 1779-1787, 2013
158. Korshunov S, Skulachev V, Starkov A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 416: 15-18, 1997
159. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100: 115-126, 1997
160. Koya D, King G. Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866, 1998
161. Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, Watanabe T, Kubota I. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13: 199-206, 2007
162. Kranstuber A, Del Rio C, Biesiadecki B, Hamlin R, Ottobre J, Gyorke S, Lacombe V. Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Front Physiol 3: 292, 2012
163. Kreppel L, Hart G. Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem 274: 32015-32022, 1999
164. Kruger NJ, von Schaewen A. The oxidative pentose phosphate pathway: structure and organisation. Curr Opin Plant Biol 6: 236-246, 2003
165. Kumar S, Sitasawad SL. N-acetylcysteine prevents glucose/glucose oxidase-induced oxidative stress, mitochondrial damage and apoptosis in H9c2 cells. Life Sci 84: 328-336, 2009
166. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814, 1997
167. Lee H, Yu M. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 65: 1170-1179, 2004
168. Lei S, Li H, Xu J, Liu Y, Gao X, Wang J, Ng KF, Lau WB, Ma XL, Rodrigues B, Irwin MG, Xia Z. Hyperglycemia-induced protein kinase Cß2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes 62: 2318-2328, 2013
169. Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis 22: 748-755, 2012
170. Leucker TM, Ge ZD, Procknow J, Liu Y, Shi Y, Bienengraeber M, Warltier DC, Kersten JR. Impairment of endothelial-myocardial interaction increases the susceptibility of cardiomyocytes to ischemia/reperfusion injury. PLoS One 8, e70088, 2013
171. Li J, Shah A. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 278: 12094-12100, 2003
172. Li L, Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 55: 1516-1523, 2006
173. Lin L. RAGE on the toll road? Cell Mol Immunol 3: 351-358, 2006
174. Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11: 191-195, 2005
175. Little WC. Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation. Circulation 112: 2888-2890, 2005
176. Liu J, Marchase RB, Chatham JC. Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol 42: 177-185, 2007
177. Liu J, Pang Y, Chang T, Bounelis P, Chatham JC, Marchase RB. Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J Mol Cell Cardiol 40: 303-312, 2006
178. Liu Q, Chen X, Macdonnell SM, Kranias EG, John N, Leitges M, Houser SR, Molkentin JD. PKCα, but not PKCβ or PKCγ, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res 105: 194-200, 2009
179. Liu Y, Qu Y, Wang R, Ma Y, Xia C, Gao C, Liu J, Lian K, Xu A, Lu X, Sun L, Yang L, Lau WB, Gao E, Koch W, Wang H, Tao L. The alternative crosstalk between RAGE and nitrative thioredoxin inactivation during diabetic myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 303: E841-E852, 2012
180. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res 2007: 61038, 2007
181. Lu L, Zhang Q, Xu Y, Zhu Z, Geng L, Wang L, Jin C, Chen Q, Schmidt A, Shen W. Intra-coronary administration of soluble receptor for advanced glycation end-products attenuates cardiac remodeling with decreased myocardial transforming growth factor-beta1 expression and fibrosis in minipigs with ischemia-reperfusion injury. Chin Med J 123: 594-958, 2010
182. Lund T, Svindland A, Pepaj M, Jensen AB, Berg JP, Kilhovd B, Hanssen KF. Fibrin(ogen) may be an important target for methylglyoxal- derived AGE modification in elastic arteries of humans. Diabetes Vasc Dis Res 8: 284-294, 2011
183. Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren J. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 13: 1751-1764, 2009
184. Maekawa K, Tanimoto T, Okada S. Gene expression of enzymes comprising the polyol pathway in various rat tissues determined by the competitive RT-PCR method. Jpn J Pharmacol 88: 123-126, 2002
185. Malhotra A, Kang B, Hashmi S, Meggs L. PKCepsilon inhibits the hyperglycemia-induced apoptosis signal in adult rat ventricular myocytes. Mol Cell Biochem 268: 169-173, 2005
186. Mapanga R, Rajamani U, Dlamini N, Zungu-Edmondson M, Kelly- Laubscher R, Shafiullah M, Wahab A, Hasan M, Fahim M, Rondeau P, Bourdon E, Essop M. Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. PLoS One 7: e47322, 2012
187. Mapanga RF, Joseph D, Symington B, Garson KL, Kimar C, Kelly- Laubscher R, Essop MF. Detrimental effects of acute hyperglycaemia on the rat heart. Acta Physiol (Oxf) 210: 546-564, 2014
188. Marshall S, Bacote V, Traxinger R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266: 4706-4712, 1991
189. Martinez-Fleites C, He Y, Davies G. Structural analyses of enzymes involved in the O-GlcNAc modification. Biochim Biophys Acta 1800: 122-133, 2010
190. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, de Caterina R, Basta G, Wautier M, Wautiers J. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53: 2662-2668, 2004
191. Masterjohn C. Regulation of methylglyoxal accumulation by glutathione and dietary antioxidants (PhD Dissertation). Storrs: University of Connecticut, 2012
192. McCarthy J, McLeod CJ, Minners J, Essop MF, Ping P, Sack MN. PKCε activation augments cardiac mitochondrial respiratory post-anoxic reserve - a putative mechanism in PKCε cardioprotection. J Mol Cell Cardiol 38: 697-700, 2005
193. Mehta NN, Sheetz M, Price K, Comiskey L, Amrutia S, Iqbal N, Mohler ER, Reilly MP. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther 23: 17-24, 2009
194. Menè P, Pascale C, Teti A, Bernardini R, Cinotti GA, Pugliese F. Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. J Am Soc Nephrol 10: 1478-1486, 1999
195. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, Ogura H, Kominami K, Onogi H, Inagi R, Nangaku M, Kurokawa K. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 60: 2351-2359, 2001
196. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13: 2478-2487, 2002
197. Mochizuki S, Neely R. Control of glyceraldehyde-3-phosphate dehydrogenase in cardiac muscle. J Mol Cell Cardiol 11: 221-236, 1979
198. Módis K, Gero D, Erdélyi K, Szoleczky P, DeWitt D, Szabo C. Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. Biochem Pharmacol 83: 633-643, 2012
199. Moncada S, Higgs E. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147, Suppl 1: S193-S201, 2006
200. Monnier V, Bautista O, Kenny D, Sell D, Fogarty J, Dahms W, Cleary P, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48: 870-880, 1999
201. Monnier V. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 419: 1-15, 2003
202. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105: 315-318, 2005
203. Namiki M, Hayashi T. A new mechanism of the Maillard reaction involving sugar fragmentation and free radical formation in The Maillard Reaction in Foods and Nutrition. In: ACS Symposium Series, 215, edited by Waller G, Feather M. Washington, DC: American Chemical Society, 1983
204. Naudi A, Jove M, Ayala V, Cassanye A, Serrano J, Gonzalo H, Boada J, Prat J, Portero-Otin M, Pamplona R. Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress. Exp Diabetes Res 2012: 696215, 2012
205. Neeper M, Schmidt A, Brett J, Yan S, Wang F, Pan Y, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992
206. Nelson MB, Swensen AC, Winden DR, Bodine JS, Bikman BT, Reynolds PR. Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation end-product signaling in a ceramidedependent manner. Am J Physiol Heart Circ Physiol 309: H63-H69, 2015
207. Newton A. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 370: 361-371, 2003
208. Nielsen JM, Kristiansen SB, Nørregaard R, Andersen CL, Denner L, Nielsen TT, Flyvbjerg A, Bøtker HE. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 11: 638-647, 2009
209. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebek D, Oatesk PJ, Hammes H, Giardino I, Brownlee M, Ave MP, York N. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000
210. Nishinaka T, Yabe-Nishimura C. EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radic Biol Med 31: 205-216, 2001
211. Nohl H. A novel superoxide radical generator in heart mitochondria. FEBS Lett 214: 269-273, 1987
212. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93: 1905-1912, 1996
213. Novotny MV, Yancey MF, Stuart R, Wiesler D, Peterson RG. Inhibition of glycolytic enzymes by endogenous aldehydes: a possible relation to diabetic neuropathies. Biochim Biophys Acta 1226: 145-150, 1994
214. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52: 864-871, 2003
215. Obsorova IG. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7: 1543-1552, 2005
216. Otter DJ, Chess-Williams R. The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats. Br J Pharmacol 113: 576-580, 1994
217. Pacher P, Obrosova I, Mabley J, Szabó C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 12: 267-275, 2005
218. Pacher P, Szabó C. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6: 136-141, 2006
219. Paradies G, Petrosillo G, Pistolese M, Venosa Di N, Federici A, Ruggiero FM. Decrease in mitochondrial complex I activity in ischemic/ reperfused rat heart: involvement of reactive oxygen species and cardiolipin. Circ Res 94: 53-59, 2004
220. Parthasarathy A, Gopi V, Devi KM, Balaji N, Vellaichamy E. Aminoguanidine inhibits ventricular fibrosis and remodeling process in isoproterenol-induced hypertrophied rat hearts by suppressing ROS and MMPs. Life Sci 118: 15-26, 2014
221. Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H. Advanced glycation endproduct- induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34: 1425-1431, 2002
222. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Les produits de Maillard (ou AGEs): leur inhibition pharmacologique au cours du diabète. Pathol Biol (Paris) 54: 405-419, 2006
223. Piarulli F, Sartore G, Lapolla A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol 50: 101-110, 2013
224. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical. Diabetes 54: 2188-2197, 2005
225. Polizzi F, Andican G, Çetin E, Civelek S, Yumuk V, Burçak G. Increased DNA-glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy. Exp Clin Endocrinol Diabetes 120: 329-334, 2012
226. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52: 2795-2804, 2003
227. Raad H, Paclet MH, Boussetta T, Kroviarski Y, Morel F, Quinn MT, Gougerot-Pocidalo MA, Dang PMC, El-Benna J. Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/ NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J 23: 1011-1022, 2009
228. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 59: 1038-1045, 2010
229. Rabbani N, Thornalley PJ. Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabetes Obes Metab 13: 577-583, 2011
230. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996
231. Rajamani U, Essop MF. Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am J Physiol Cell Physiol 299: C139-C147, 2010
232. Rajamani U, Joseph D, Roux S, Essop MF. The hexosamine biosynthetic pathway can mediate myocardial apoptosis in a rat model of diet-induced insulin resistance. Acta Physiol (Oxf) 202: 151-157, 2011
233. Rajapakse A, Ming X, Carvas J, Yang Z. O-linked beta-N-acetylglucosamine during hyperglycemia exerts both anti-inflammatory and prooxidative properties in the endothelial system. Oxid Med Cell Longev 2: 172-175, 2009
234. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J 18: 1209-1218, 2004
235. Ramasamy R, Liu H, Oates PJ, Schaefer S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. Cardiovasc Res 42: 130-139, 1999
236. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition improves the altered glucose metabolism of isolated diabetic rat hearts. Diabetes 46: 292-300, 1997
237. Ramasamy R, Trueblood NA, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 275: H195-H203, 1998
238. Ramirez-Correa GA, Ma J, Slawson C, Zeidan Q, Lugo-Fagundo NS, Xu M, Shen X, Gao WD, Caceres V, Chakir K, DeVine L, Cole RN, Marchionni L, Paolocci N, Hart GW, Murphy AM. Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ sensitivity in diabetic cardiac muscle. Diabetes 64: 3573-3587, 2015
239. Ranganathan S, Ciaccio P, Walsh E, Tew K. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 240: 149-155, 1999
240. Raposeiras-Roubín S, Rodiño-Janeiro BK, Paradela-Dobarro B, Grigorian-Shamagian L, García-Acuña JM, Aguiar-Souto P, Jacquet- Hervet M, Reino-Maceiras MV, Alvarez E, González-Juanatey JR. Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report. Cardiovasc Diabetol 11: 102, 2012
241. Reddy AB, Ramana KV. Aldose reductase inhibition: emerging drug target for the treatment of cardiovascular complications. Recent Pat Cardiovasc Drug Discov 5: 25-32, 2010
242. Reusch JE. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 112: 986-988, 2003
243. Rodiño-Janeiro BK, González-Peteiro M, Ucieda-Somoza R, González-Juanatey JR, Álvarez E. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev 26: 550-558, 2010
244. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y; American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-e171, 2007
245. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289: F420-F430, 2005
246. Ruf T, Quintes S, Sternik P, Gottmann U. Atorvastatin reduces the expression of aldo-keto reductases in HUVEC and PTEC. A new approach to influence the polyol pathway. Clin Invest Med 32: E219-E228, 2009
247. Sage A, Walter L, Shi Y, Khan M, Kaneto H, Capretta A, Werstuck G. Hexosamine biosynthesis pathway flux promotes endoplasmic reticulum stress, lipid accumulation, and inflammatory gene expression in hepatic cells. Am J Physiol Endocrinol Metab 298: E499-E511, 2010
248. Sakurai S. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 14: 259S-263S, 2003
249. Saxena A, Saxena P, Wu X, Obrenovich M, Weiss M, Monnier V. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 260: 332-338, 1999
250. Schaffer SW, Jong CJ, Mozaffari M. Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vascul Pharmacol 57: 139-149, 2012
251. Schenk G, Duggleby RG, Nixon PF. Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Int J Biochem Cell Biol 30: 1297-1318, 1998
252. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-_II in neonatal mesangial cells. Am J Physiol Renal Physiol 278: F676-F683, 2000
253. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 57: 1874-1880, 2009
254. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 22: 74-79, 2009
255. Sheetz M, King G. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 288: 2579-2588, 2002
256. Shiba T, Inoguchi T, Sportsman J, Heath W, Bursell S, King G. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol Endocrinol Metab 265: E783- E793, 1993
257. Shiba T, Inoguchi T, Sportsman J, Heath W, Bursell S, King G. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol Endocrinol Metab 265: E783- E793, 1993
258. Shizukuda Y, Reyland ME, Buttrick PM. Protein kinase C-_ modulates apoptosis induced by hyperglycemia in adult ventricular myocytes. Am J Physiol Heart Circ Physiol 282: H1625-H1634, 2002
259. Simpson PC. Beta-protein kinase C and hypertrophic signaling in human heart failure. Circulation 99: 334-337, 1999
260. Sims MW, Winter J, Brennan S, Norman RI, Ng GA, Squire IB, Rainbow RD. PKC-mediated toxicity of elevated glucose concentration on cardiomyocyte function. Am J Physiol Heart Circ Physiol 307: H587-H597, 2014
261. Skulachev V. Anion carriers in fatty acid-mediated physiological uncoupling. J Bioenerg Biomembr 31: 431-445, 1999
262. Son H, Kim H, Kwon Y. Taurine prevents oxidative damage of high glucose-induced cataractogenesis in isolated rat lenses. J Nutr Sci Vitaminol (Tokyo) 53: 324-330, 2007
263. Son NH, Ananthakrishnan R, Yu S, Khan RS, Jiang H, Ji R, Akashi H, Li Q, O’Shea K, Homma S, Goldberg IJ, Ramasamy R. Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. PLoS One 7: 1-11, 2012
264. Song X, Qian X, Shen M, Jiang R, Wagner MB, Ding G, Chen G, Shen B. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta 1853: 513-521, 2015
265. Sorescu D, Weiss D, Lassègue B, Clempus R, Szöcs K, Sorescu G, Valppu L, Quinn M, Lambeth J, Vega J, Taylor W, Griendling K. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429-1435, 2002
266. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053-1059, 2001
267. Springhorn C, Matsha T, Erasmus R, Essop M. Exploring leukocyte O-GlcNAcylation as a novel diagnostic tool for the earlier detection of type 2 diabetes mellitus. J Clin Endocrinol Metab 97: 4640-4649, 2012
268. Srinivasan S, Hatley M, Bolick D, Palmer L, Edelstein D, Brownlee M, Hedrick C. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 47: 1727-1734, 2004
269. Srinivasan V, Sandhya N, Sampathkumar R, Farooq S, Mohan V, Balasubramanyam M. Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress. Clin Biochem 40: 952-957, 2007
270. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26: 380-392, 2005
271. Srivastava SK, Ramana KV, Chandra D, Srivastava S, Bhatnagar A. Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chem Biol Interact 143-144: 333-340, 2003
272. Strasser RH, Braun-Dullaeus R, Walendzik H, Marquetant R. Alpha 1-receptor-independent activation of protein kinase C in acute myocardial ischemia. Mechanisms for sensitization of the adenylyl cyclase system. Circ Res 70: 1304-1312, 1992
273. Sugimoto K, Ohkawara H, Nakamura Y, Takuwa Y, Ishibashi T, Takeishi Y. Receptor for advanced glycation end products - membrane type1 matrix metalloproteinase axis regulates tissue factor expression via RhoA and Rac1 activation in high-mobility group Box-1 stimulated endothelial cells. PLoS One 9: e114429, 2014
274. Szabó C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 140-141: 105-112, 2003
275. Tammali R, Saxena A, Srivastava SK, Ramana KV. Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle. Endocrinology 151: 2140-2150, 2010
276. Tang WH, Cheng WT, Kravtsov GM, Tong XY, Hou XY, Chung SK, Chung SS. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol 299: C643-C653, 2010
277. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 3: 87, 2012
278. Taylor CT, Moncada S. Nitric oxide, cytochrome C oxidase, and the cellular response to hypoxia. Arterioscler Thromb Vasc Biol 30: 643-647, 2010
279. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 16: 383-391, 1994
280. Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM. Inhibition of NADPH oxidase prevents advanced glycation end productmediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57: 460-469, 2008
281. Thornalley P, Yurek-George A, Argirov O. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60: 55-65, 2000
282. Thornalley P. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419: 31-40, 2003
283. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 111: 137-151, 1998
284. Tikellis C, Pickering RJ, Tsorotes D, Huet O, Cooper ME, Jandeleit- Dahm K, Thomas MC. Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 63: 3915-3925, 2014
285. Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun 390: 877-882, 2009
286. Torres C, Hart G. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 259: 3308-3317, 1984
287. Toth E, Racz A, Toth J, Kaminski PM, Wolin MS, Bagi Z, Koller A. Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH2/TXA2 mediation. Am J Physiol Heart Circ Physiol 293: H3096-H3104, 2007
288. Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, Oates PJ. Aldose reductase inhibition alone or combined with an adenosine A3 agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol 279: H1447-H1452, 2000
289. Travis S, Morrison A, Clements RJ, Winegrad A, Oski F. Metabolic alterations in the human erythrocyte produced by increases in glucose concentration. The role of the polyol pathway. J Clin Invest 50: 2104-2112, 1971
290. Trueblood N, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol Heart Circ Physiol 275: H75-H83, 1998
291. Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 106: 93-101, 2010
292. Turk Z, Ljubic S, Turk N, Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 303: 105-115, 2001
293. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690, 2005
294. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 56: 1-21, 2001
295. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with T2DM (UKPDS 33). Lancet 352: 837-845, 1998
296. Urios P, Grigorova-Borsos AM, Sternberg M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 77: 337-340, 2007
297. Vander Jagt DL, Hassebrook RK, Hunsaker LA, Brown WM, Royer RE. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact 130-132: 549-562, 2001
298. Vander Jagt DL, Robinson B, Taylor KK, Hunsaker LA. Aldose reductase from human skeletal and heart muscle: interconvertible forms related by thiol-disulfide exchange. J Biol Chem 265: 20982-20987, 1990
299. van Eupen MG, Schram MT, Colhoun HM, Hanssen NM, Niessen HW, Tarnow L, Parving HH, Rossing P, Stehouwer CD, Schalkwijk CG. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia 56: 1845-1855, 2013
300. Van Eupen MG, Schram MT, Colhoun HM, Scheijen JL, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts are associate with type 1 diabetes and coronary artery calcification. Cardiovasc Diabetol 12: 149, 2013
301. van Herpen N, Schrauwen-Hinderling V. Lipid accumulation in nonadipose tissue and lipotoxicity. Physiol Behav 94: 231-241, 2008
302. van Heyningen R. Sugar alcohols in the pathogenesis of galactose and diabetic cataracts. Birth Defects Orig Artic Ser 12: 295-303, 1976
303. Vedantham S, Noh H, Ananthakrishnan R, Son N, Hallam K, Hu Y, Yu S, Shen X, Rosario R, Lu Y, Ravindranath T, Drosatos K, Huggins LA, Schmidt AM, Goldberg IJ, Ramasamy R. Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E_/_ mice. Arterioscler Thromb Vasc Biol 31: 1805-1813, 2011
304. Vigetti D, Deleonibus S, Moretto P, Bowen T, Fischer JW, Grandoch M, Oberhuber A, Love DC, Hanover JA, Cinquetti R, Karousou E, Viola M, D’Angelo ML, Hascall VC, De Luca G, Passi A. Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via protein O-GlcNAcylation. J Biol Chem 289: 28816-28826, 2014
305. Vincent A, Russell J, Low P, Feldman E. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25: 612-628, 2004
306. Vinik A, Flemmer M. Diabetes and macrovascular disease. J Diabetes Complications 16: 235-245, 2002
307. Virág L, Szabó E, Gergely P, Szabó C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 140-141: 113-124, 2003
308. Vlassara H, Palace M. Diabetes and advanced glycation endproducts. J Intern Med 251: 87-101, 2002
309. Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94: 9320-9325, 1997
310. Wamelink MM, Struys EA, Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. J Inherit Metab Dis 31: 703-717, 2008
311. Wang X, Lau W, Yuan Y, Wang Y, Yi W, Christopher T, Lopez B, Liu H, Ma X. Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity. Am J Physiol Endocrinol Metab 299: E207-E214, 2010
312. Watkins N, Thorpe S, Baynes J. Glycation of amino groups in protein. Studies on the specificity of modification of RNase by glucose. J Biol Chem 260: 10629-10636, 1985
313. Watson AM, Li J, Samijono D, Bierhaus A, Thomas MC, Jandeleit- Dahm KA, Cooper ME. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. Atherosclerosis 235: 444-448, 2014
314. Wei L, Sun D, Yin Z, Yuan Y, Hwang A, Zhang Y, Si R, Zhang R, Guo W, Cao F, Wang H. A PKC-_ inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats. Apoptosis 15: 488-498, 2010
315. Wei L, Yin Z, Yuan Y, Hwang A, Lee A, Sun D, Li F, Di C, Zhang R, Cao F, Wang H. A PKC-_ inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats. Microvasc Res 80: 158-165, 2010
316. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong L, Jenkins D, Stein G, Schmidt A, Yan S. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185: 70-77, 2006
317. Werstuck G, Khan M, Femia G, Kim A, Tedesco V, Trigatti B, Shi Y. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes 55: 93-101, 2006
318. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993
319. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of “autoxidative glycosylation” in diabetes. Biochem J 245: 243-250, 1987
320. Wright KJ, Thomas MM, Betik AC, Belke D, Hepple RT. Exercise training initiated in late middle age attenuates cardiac fibrosis and advanced glycation end-product accumulation in senescent rats. Exp Gerontol 50: 9-18, 2014
321. Wu L, Juurlink BH. Increased methyglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39: 809-814, 2002
322. Xia L, Wang H, Goldberg HJ, Munk S, Fantus IG, Whiteside CI. Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am J Physiol Renal Physiol 290: F345-F356, 2006
323. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol- protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43: 1122-1129, 1994
324. Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na_,K_-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 96: 733-740, 1995
325. Xia Z, Kuo KH, Nagareddy PR, Wang F, Guo Z, Guo T, Jiang J, McNeill JH. N-acetylcysteine attenuates PKCbeta2 overexpression andmyocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 73: 770-782, 2007
326. Xu P, Wang J, Kodavatiganti R, Zeng Y, Kass IS. Activation of protein kinase C contributes to the isoflurane-induced improvement of functional and metabolic recovery in isolated ischemic rat hearts. Anesth Analg 99: 993-1000, 2004
327. Yabe-Nishimura C, Nishinaka T, Iwata K, Seo HG. Up-regulation of aldose reductase by the substrate, methylglyoxal. Chem Biol Interact 143-144: 317-323, 2003
328. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50: 21-33, 1998
329. Yamakawa T, Tanaka S, Yamakawa Y, Kamei J, Numaguchi K, Motley E, Inagami T, Eguchi S. Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 22: 752-758, 2002
330. Yan D, Luo X, Li Y, Liu W, Deng J, Zheng N, Gao K, Huang Q, Liu J. Effects of advanced glycation end products on calcium handling in cardiomyocytes. Cardiology 129: 75-83, 2014
331. Yan H, Guo Y, Zhang J, Ding Z, Ha W, Harding J. Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. Mol Vis 14: 2282-2291, 2008
332. Yan S, Schmidt A, Anderson G, Zhang J, Brett J, Zou Y, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897, 1994
333. Ying W. NADP_/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10: 179-206, 2008
334. Yki-Järvinen H, Daniels M, Virkamäki A, Mäkimattila S, DeFronzo R, McClain D. Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 45: 302-307, 1996
335. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Current perspective roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 311: 305-311, 2005
336. Yoon SJ, Park S, Park C, Chang W, Cho DK, Ko YG, Choi D, Kwon HM, Jang Y, Chung N. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Coron Artery Dis 23: 85-90, 2012
337. Yuan Q, Zhou QY, Liu D, Yu L, Zhan L, Li XJ, Peng HY, Zhang XL, Yuan XC. Advanced glycation end-products impair Na/K-ATPase activity in diabetic cardiomyopathy: role of the adenosine monophosphate- activated protein kinase/sirtuin 1 pathway. Clin Exp Pharmacol Physiol 41: 127-133, 2014
338. Zachara NE, Hart GW.Cell signaling, the essential role of O-GlcNAc! Biochim Biophys Acta 1761: 599-617, 2006
339. Zachara NE, O’Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress: a survival response of mammalian cells. J Biol Chem 279: 30133-30142, 2004
340. Zeng C, Wang J, Li N, Shen M, Wang D, Yu Q, Wang H. AKAP150 mobilizes cPKC-dependent cardiac glucotoxicity. Am J Physiol Endocrinol Metab 307: E384-E397, 2014
341. Zhang M, Ay LK, Anilkumar N, Chibber R, Pagano PJ, Shah AM, Cave AC. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: Involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 113: 1235-1243, 2006
342. Zhang M, Shah AM. ROS signalling between endothelial cells and cardiac cells. Cardiovasc Res 102: 249-257, 2014
343. Zhang S, Li H, Yang SJ. Tribulosin protects rat hearts from ischemia/ reperfusion injury. Acta Pharmacol Sin 31: 671-678, 2010
344. Zhang T, Hu X, Cai Y, Yi B, Wen Z. Metformin protects against hyperglycemia-induced cardiomyocytes injury by inhibiting the expressions of receptor for advanced glycation end products and high mobility group box 1 protein. Mol Biol Rep 41: 1335-1340, 2014
345. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies JA. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 265: 16330-16336, 1990
346. Zhao J. Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart. World J Diabetes 5: 860, 2014
347. Zheng H, Li Y, Xie N, Huang JL, Xu HF, Luo M. Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients. Genet Mol Res 14: 3775-3783, 2015
348. Zhou L, Aon M, Almas T, Cortassa S, Winslow R, O’Rourke B. A reaction-diffusion model of ROS-induced ROS release in a mitochondrial network. PLoS Comput Biol 6: e1000657, 2010
349. Zhu WW, Liu XP, Wu N, Zhao TT, Zhao Y, Zhang J, Shao JH. Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats. Mol Cell Biochem 304: 35-43, 2007
350. Ziegler D, Mayer P, Rathmann W, Gries F. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 14: 63-73, 1991
351. Zieman S, Kass D. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64: 459-470, 2004